The company is scaling up manufacturing and commercial activities as it prepares to enter the U.S. market via the Food and Drug Administration’s de novo pathway.

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood ...

The specimen of choice that enables the collection of small blood volumes from neonatal or critically ill patients is a capillary blood specimen. This specimen type has gained favour with many ...

Jan 19 (Reuters) - The U.S. health regulator said on Wednesday it was expanding the medical device shortage list to include all blood specimen collection tubes due to supply challenges led by an ...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of ...

The global blood collection devices market is set to grow from USD 9.13 billion in 2025 to USD 13.02 billion by 2030, with a ...

SEATTLE, March 5, 2025 /PRNewswire/ — Magnolia Medical Technologies, Inc., the pioneer in Initial Specimen Diversion Device ® (ISDD ®) technology, today announced groundbreaking new findings from an ...

The FDA is recommending that healthcare providers only perform blood draws considered medically necessary, after interruptions in the nationwide supply chain and the COVID-19 pandemic have caused ...